{"id":3223,"date":"2025-01-10T16:07:44","date_gmt":"2025-01-10T08:07:44","guid":{"rendered":"\/\/www.axcessimc.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%b0%91%e5%be%97%e7%bb%b4%e6%b2%bb%e7%96%97%e6%96%b0%e5%86%a0%e8%8e%b7%e5%b8%b8%e8%a7%84%e6%89%b9%e5%87%86\/"},"modified":"2025-01-14T16:09:58","modified_gmt":"2025-01-14T08:09:58","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%b0%91%e5%be%97%e7%bb%b4%e6%b2%bb%e7%96%97%e6%96%b0%e5%86%a0%e8%8e%b7%e5%b8%b8%e8%a7%84%e6%89%b9%e5%87%86","status":"publish","type":"post","link":"\/\/www.axcessimc.com\/zh-hant\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%b0%91%e5%be%97%e7%bb%b4%e6%b2%bb%e7%96%97%e6%96%b0%e5%86%a0%e8%8e%b7%e5%b8%b8%e8%a7%84%e6%89%b9%e5%87%86\/","title":{"rendered":"\u541b\u5be6\u751f\u7269\u5ba3\u4f48\u6c11\u5f97\u7dad\u00ae\u6cbb\u7642\u65b0\u51a0\u7372\u5e38\u898f\u6279\u51c6"},"content":{"rendered":"\n
\u5317\u4eac\u6642\u95932025\u5e741\u670810\u65e5\uff0c\u541b\u5be6\u751f\u7269\uff081877.HK\uff0c688180.SH\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u65d7\u4e0b\u7684\u53e3\u670d\u6838\u82f7\u985e\u6297\u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\uff08SARS-CoV-2\uff09\u85e5\u7269\u6c11\u5f97\u7dad\u00ae<\/sup>\uff08\u6c2b\u6eb4\u9178\u6c18\u745e\u7c73\u5fb7\u97cb\u7247\uff0c\u7522\u54c1\u4ee3\u865f\uff1aVV116\/JT001\uff09\u7528\u65bc\u6cbb\u7642\u8f15\u4e2d\u5ea6\u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\uff08COVID-19\uff09\u7684\u6210\u5e74\u60a3\u8005\u7684\u9069\u61c9\u75c7\u6b63\u5f0f\u7372\u5f97\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u540c\u610f\uff0c\u7531\u9644\u689d\u4ef6\u6279\u51c6\u8f49\u70ba\u5e38\u898f\u6279\u51c6\u3002<\/p>\n\n\n\n 2023\u5e741\u670828\u65e5\uff0c\u57fa\u65bc\u4e00\u9805\u5728\u4f34\u6216\u4e0d\u4f34\u6709\u9032\u5c55\u70ba\u91cd\u75c7\u9ad8\u98a8\u96aa\u56e0\u7d20\u7684\u8f15\u4e2d\u5ea6COVID-19\u60a3\u8005\u4e2d\u958b\u5c55\u7684\u591a\u4e2d\u5fc3\u3001\u96d9\u76f2\u3001\u96a8\u6a5f\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u2162\u671f\u81e8\u5e8a\u7814\u7a76\uff08JT001-015\u7814\u7a76\uff0cNCT05582629\uff09\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u7372\u5f97\u570b\u5bb6\u85e5\u76e3\u5c40\u9644\u689d\u4ef6\u4e0a\u5e02\u6279\u51c6\u3002<\/p>\n\n\n\n \u6b64\u6b21\u6c11\u5f97\u7dad\u00ae<\/sup>\u5e38\u898f\u6279\u51c6\u57fa\u65bc\u591a\u9805\u81e8\u5e8a\u53ca\u975e\u81e8\u5e8a\u7814\u7a76\uff0c\u5305\u62ecJT001-015\u7814\u7a76\u548c\u4e00\u9805\u7d0d\u5165\u8fd18000\u4f8b\u60a3\u8005\u7684\u771f\u5be6\u4e16\u754c\u7814\u7a76\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u5728\u8f15\u3001\u4e2d\u5ea6\u65b0\u51a0\u60a3\u8005\u4e2d\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u53ef\u986f\u8457\u52a0\u901f\u75c7\u72c0\u7de9\u89e3\u548c\u6d88\u5931\u3001\u7e2e\u77ed\u75c5\u7a0b\uff0c\u52a0\u5feb\u75c5\u6bd2\u8f49\u9670\uff0c\u964d\u4f4e\u91cd\u75c7COVID-19\u6216\u5168\u56e0\u6b7b\u4ea1\u767c\u751f\u7387\uff0c\u5c0d\u8001\u5e74\u548c\u9ad8\u98a8\u96aa\u60a3\u8005\u6548\u679c\u66f4\u986f\u8457\u3002\u5728\u8f15\u4e2d\u5ea6\u809d\u814e\u529f\u80fd\u4e0d\u5168\u7684\u60a3\u8005\u4e2d\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\uff0c\u60a3\u8005\u5728\u670d\u85e5\u904e\u7a0b\u4e2d\u7121\u9700\u6216\u50c5\u9700\u5c11\u91cf\u8abf\u6574\u7528\u85e5\u5291\u91cf\u3002\u540c\u6642\uff0c\u85e5\u7406\u7814\u7a76\u986f\u793a\u6c11\u5f97\u7dad\u00ae<\/sup>\u57fa\u672c\u7121\u85e5\u7269\u9593\u76f8\u4e92\u4f5c\u7528\uff0c\u5927\u5927\u6e1b\u5c11\u4e86\u7528\u85e5\u7981\u5fcc\uff0c\u6709\u6548\u4fdd\u969c\u60a3\u8005\u7684\u5408\u4f75\u7528\u85e5\uff0c\u70ba\u7279\u6b8a\u4eba\u7fa4\u63d0\u4f9b\u4e86\u66f4\u5b89\u5168\u3001\u66f4\u6709\u6548\u7684\u9078\u64c7\u3002<\/p>\n\n\n\n \u6b64\u5916\uff0c\u76f8\u95dc\u7814\u7a76\u8868\u660e\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u53ef\u986f\u8457\u6291\u5236\u65b0\u51a0\u75c5\u6bd2XBB.1.16\u3001EG.5\u3001JN.1\u8b8a\u7570\u682a\uff0c\u5c0d\u4e3b\u8981\u6d41\u884c\u682a\u6301\u7e8c\u6709\u6548\u3002<\/p>\n\n\n\n \u6c11\u5f97\u7dad\u00ae<\/sup>\u4e0a\u5e02\u4ee5\u4f86\uff0c\u53ef\u53ca\u6027\u4e0d\u65b7\u63d0\u5347\uff0c\u81ea2024\u5e741\u67081\u65e5\u8d77\u88ab\u6b63\u5f0f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u6bcf\u500b\u7642\u7a0b\u50f9\u683c\u70ba475\u5143\uff0c\u6309\u7167\u4e59\u985e\u91ab\u4fdd\u5831\u92b7\uff0c\u5927\u5e45\u4f4e\u65bc\u540c\u985e\u9032\u53e3\u7522\u54c1\u3002\u60a3\u8005\u53ef\u5728\u91ab\u9662\u53ca\u4e92\u806f\u7db2\u91ab\u9662\u5c31\u8a3a\u8cfc\u8cb7\uff0c\u986f\u8457\u63d0\u5347\u4e86\u6297\u75c5\u6bd2\u85e5\u7269\u7684\u53ef\u53ca\u6027\u548c\u4fbf\u5229\u6027\u3002<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n \u95dc\u65bc\u6c2b\u6eb4\u9178\u6c18\u745e\u7c73\u5fb7\u97cb\u7247\uff08\u6c11\u5f97\u7dad<\/strong>\u00ae<\/sup><\/strong>\uff0c<\/strong>VV116\/JT001<\/strong>\uff09<\/strong><\/strong><\/p>\n\n\n\n \u6c11\u5f97\u7dad\u00ae<\/sup>\u662f\u4e00\u6b3e\u53e3\u670d\u6838\u82f7\u985e\u85e5\u7269\uff0c\u53ef\u6291\u5236SARS-CoV-2\u8907\u88fd\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u986f\u793a\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u5c0d\u5305\u62ec\u5967\u5bc6\u514b\u620e\u5728\u5167\u7684\u65b0\u51a0\u75c5\u6bd2\u539f\u59cb\u682a\u548c\u7a81\u8b8a\u682a\u8868\u73fe\u51fa\u986f\u8457\u7684\u6297\u75c5\u6bd2\u4f5c\u7528\uff0c\u4e14\u7121\u907a\u50b3\u6bd2\u6027\u3002\u8a72\u7522\u54c1\u7531\u4e2d\u570b\u79d1\u5b78\u9662\u4e0a\u6d77\u85e5\u7269\u7814\u7a76\u6240\u3001\u4e2d\u570b\u79d1\u5b78\u9662\u6b66\u6f22\u75c5\u6bd2\u7814\u7a76\u6240\u3001\u4e2d\u570b\u79d1\u5b78\u9662\u65b0\u7586\u7406\u5316\u6280\u8853\u7814\u7a76\u6240\u3001\u4e2d\u570b\u79d1\u5b78\u9662\u4e2d\u4e9e\u85e5\u7269\u7814\u767c\u4e2d\u5fc3\/\u4e2d\u70cf\u91ab\u85e5\u79d1\u6280\u57ce\uff08\u79d1\u6280\u90e8\u201c\u4e00\u5e36\u4e00\u8def\u201d\u806f\u5408\u5be6\u9a57\u5ba4\uff09\u3001\u81e8\u6e2f\u5be6\u9a57\u5ba4\u3001\u8607\u5dde\u65fa\u5c71\u65fa\u6c34\u751f\u7269\u91ab\u85e5\u6709\u9650\u516c\u53f8\u548c\u541b\u5be6\u751f\u7269\u5171\u540c\u7814\u767c\u3002<\/p>\n\n\n\n \u5728\u65b0\u51a0\u75ab\u60c5\u671f\u9593\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u5728\u570b\u5167\u5916\u958b\u5c55\u4e86\u591a\u9805\u81e8\u5e8a\u7814\u7a76\u3002\u4e00\u9805\u5728\u4f34\u6709\u9032\u5c55\u70ba\u91cd\u75c7\u9ad8\u98a8\u96aa\u56e0\u7d20\u7684\u8f15\u4e2d\u5ea6COVID-19\u60a3\u8005\u4e2d\u5c0d\u6bd4PAXLOVID\u7528\u65bc\u8f15\u4e2d\u5ea6COVID-19\u65e9\u671f\u6cbb\u7642\u7684\u2162\u671f\u81e8\u5e8a\u7814\u7a76\uff08JT001-010\uff09\u7372\u5f97\u570b\u969b\u6b0a\u5a01\u671f\u520a\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b\uff08The New England Journal of Medicine<\/em>\uff0cIF\uff1a96.2\uff09\u767c\u8868[1]<\/sup>\uff0c\u53e6\u4e00\u9805\u5728\u4f34\u6216\u4e0d\u4f34\u6709\u9032\u5c55\u70ba\u91cd\u75c7\u9ad8\u98a8\u96aa\u56e0\u7d20\u7684\u8f15\u4e2d\u5ea6COVID-19\u60a3\u8005\u4e2d\u958b\u5c55\u7684\u2162\u671f\u81e8\u5e8a\u7814\u7a76\uff08JT001-015\uff09\u7372\u5f97\u570b\u969b\u9802\u5c16\u611f\u67d3\u75c5\u5b78\u671f\u520a\u300a\u67f3\u8449\u5200-\u611f\u67d3\u75c5\u5b78\u300b\uff08The Lancet Infectious Diseases<\/em>\uff0cIF\uff1a36.4\uff09\u767c\u8868[2]<\/sup>\u3002<\/p>\n\n\n\n 2021\u5e7412\u6708\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u5728\u70cf\u8332\u5225\u514b\u65af\u5766\u7372\u5f97\u6279\u51c6\u7528\u65bc\u6cbb\u7642\u4e2d\/\u91cd\u5ea6COVID-19\u60a3\u8005\u3002<\/p>\n\n\n\n 2023\u5e741\u6708\uff0c\u6c11\u5f97\u7dad\u00ae<\/sup>\u5728\u4e2d\u570b\u7372\u5f97\u6279\u51c6\u7528\u65bc\u6cbb\u7642\u8f15\u4e2d\u5ea6COVID-19\u7684\u6210\u5e74\u60a3\u8005\uff0c\u4e26\u4e8e2023\u5e741\u6708\u8d77\u81e8\u6642\u6027\u7d0d\u5165\u91ab\u4fdd\u652f\u4ed8\u7bc4\u570d\uff0c2024\u5e741\u6708\u8d77\u7d0d\u5165\u6b63\u5f0f\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002<\/p>\n\n\n\n \u7528\u65bc\u6cbb\u7642\u8f15\u4e2d\u5ea6\u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\uff08COVID-19\uff09\u7684\u6210\u5e74\u60a3\u8005<\/p>\n","protected":false},"author":4,"featured_media":3217,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[],"class_list":["post-3223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-21"],"yoast_head":"\n1. <\/em>\u672c\u6750\u6599\u65e8\u5728\u50b3\u905e\u524d\u6cbf\u8cc7\u8a0a\uff0c\u7121\u610f\u5411\u60a8\u505a\u4efb\u4f55\u7522\u54c1\u7684\u63a8\u5ee3\uff0c\u4e0d\u4f5c\u70ba\u81e8\u5e8a\u7528\u85e5\u6307\u5c0e\u3002<\/em><\/em><\/h6>\n\n\n\n
2. <\/em>\u82e5\u60a8\u60f3\u77ad\u89e3\u5177\u9ad4\u75be\u75c5\u8a3a\u7642\u8cc7\u8a0a\uff0c\u8acb\u9075\u5f9e\u91ab\u7642\u885b\u751f\u5c08\u696d\u4eba\u58eb\u7684\u610f\u898b\u8207\u6307\u5c0e\u3002<\/em><\/em><\/h6>\n\n\n\n
\u3010\u53c3\u8003\u6587\u737b\u3011<\/h5>\n\n\n\n
[1] Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir\u2013Ritonavir for Oral Treatment of Covid-19. N Engl J Med. DOI: 10.1056\/NEJMoa2208822.<\/h5>\n\n\n\n
[2] Xiaohong Fan, Xiahong Dai, Yun Ling, et al. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. The Lancet Infectious Diseases. DOI:10.1016\/S1473-3099(23)00577-7.<\/h5>\n","protected":false},"excerpt":{"rendered":"